Next Generation Fecal Microbiota Transplantation.

Area of Science:

• Microbiology
• Gastroenterology
• Infectious Diseases

Background:

• Clostridioides difficile infection (CDI) is a significant healthcare challenge.
• Fecal microbiota transplantation (FMT) is a highly effective treatment for recurrent CDI.
• The exact therapeutic mechanisms of FMT remain incompletely understood.

Purpose of the Study:

• To review the current understanding of FMT for CDI treatment.
• To discuss the composition and processing of stool for FMT.
• To highlight advancements in FMT technology and analysis.

Main Methods:

• Review of existing literature on FMT for CDI.
• Analysis of stool composition, including microbiota, debris, and metabolites.
• Discussion of various FMT delivery methods (fresh, frozen, capsules).

Main Results:

• FMT efficacy in treating CDI is well-established.
• Intestinal microbiota is the primary driver of FMT's therapeutic effect.
• Frozen stool and encapsulated formulations demonstrate comparable efficacy to fresh stool.
• Novel stool products and stool banking initiatives are emerging.
• Next-generation sequencing aids in analyzing donor and recipient microbiota.

Conclusions:

• FMT is a crucial treatment for CDI, with the gut microbiota being the key therapeutic component.
• Standardization of stool processing and product development are advancing FMT accessibility.
• Technological advancements, particularly in sequencing, are enhancing the understanding and application of FMT.